Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure News-Medical.net Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b ... Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of ... |
